Wednesday, November 15, 2006

Cancer kinase inhibitors for hypertension too?

Researchers believe that Nexavar (competitor to Sutent) may prevent pulmonary hypertension, in addition to its’ anti-cancer properties. (The article doesn’t state which target Nexavar blocks to counter hypertension.)

It’s been long talked about that cancer and inflammation are linked diseases, with some even suggesting that they’re the same disease (and managed by IKK kinase), so the Nexavar finding isn’t shocking, but it’s most important implication may be an extended application for this class of drug.

In spite of this news, stock in Onyx (Nexavar's maker) dropped 1.8%. I still think Onyx is a buy, as I detailed here:

No comments: